Innovega e macula eyewear 2019

Description
1. 1 SMART CONTACT LENSES and STYLISH GLASSES Patients and Consumers COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and iOptik is a registered trademark, of…

Please download to get full document.

View again

of 20
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Information
Category:

Mobile

Publish on:

Views: 0 | Pages: 20

Extension: PDF | Download: 0

Share
Transcript
  • 1. 1 SMART CONTACT LENSES and STYLISH GLASSES Patients and Consumers COPYRIGHT Innovega Inc. 2018. eMacula is a trademark, and iOptik is a registered trademark, of Innovega Inc. Engineered by Innovega Inc.
  • 2. 2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements and information relating to, among other things, Innovega Inc, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events based on information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they are meant for illustrative purposes and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which guarantees cannot be made. Moreover, no person or entity assumes responsibility for the accuracy and completeness of these forward-looking statements, and no persons or entities are under any duty to update any such statements to conform them to actual results. 2
  • 3. 3 TRANSFORMATIVE EYEWEAR SYSTEM • Transformative for • Partially-sighted patients who have lost their lifestyle • An Industry whose growth has stalled and is in need of innovation • Normal, Stylish Glasses for medical, consumer and industrial applications • 30 domestic plus additional international patents plus trade-secrets • The company will initially license its technology into the $74B global vision care market • Advisor teams include senior executives from Microsoft, Sony and Bausch + Lomb 3
  • 4. 4 EMACULA™ SYSTEM UNPRECEDENTED ASSISTANCE FOR 15 M VISUALLY IMPAIRED PATIENTS • Problem: Patients with visual impairment require magnification to see what a sighted person sees • The magnification required by patient is too great for normal prescription eyeglasses or contact lenses • Innovega Cameral on Glasses Solution: Camera mounted on glasses captures, magnifies, and enhances the patient’s world to instantly deliver functional vision • Patient wears Innovega smart contact lens and glasses that instantly deliver magnified, enhanced and panoramic sight from lightweight, stylish eyewear system 4
  • 5. 55 SMART PERSONALIZED CONTACT LENSES PROPRIETARY NANO-TECHNOLOGY POLARIZERS Outer Filter & Lens Capturing Real-World View Contact Lens Will include Personal Prescription Center Filter & Lenslet Capturing Digital Media 5
  • 6. 6 MANY SMART GLASSES CONFIGURATIONS AR Panoramic AR Mobile VR Lite VR Immersive
  • 7. 7 INNOVEGA TEAM Steve Willey: Co-Founder, CEO & Director — Passion for commercializing game-changing technologies (Co-founder and president, MicroVision (NASDAQ: MVIS); “turn-around” CEO of AirIQ Inc (TSXV:IQ) ; multiple business and general management of start-ups that were later acquired by Fortune 100 companies. Jay Marsh: VP Engineering — Former VP Engineering with APRI, and more than 25 years developing systems that achieved unprecedented performance; leadership of multidisciplinary engineering teams dedicated to delivering complex electro / optical / mechanical systems Dr. Jerome A. Legerton: Co-Founder, Director — Successful career in contact lens development and commercialization; 56 issued U.S. patents, co-inventor of Paragon CRT® contact lenses, the market leader for overnight corneal reshaping. Co-founder and former CTO and EVP of SynergEyes, Inc., the world leader in hybrid contact lenses. 7
  • 8. 8 LARGE PATIENT AND CONSUMER MARKETS 8 https://www.prnewswire.com/news- releases/global-74-bn-vision-care-market-to-2024- 300817009.html https://www.grandviewresearch.com/industry- analysis/contact-lenses-market https://www.marketwatch.com/press-release/ar-and-vr-smart- glasses-market-2019-global-size-share-trends-growth- opportunities-key-players-industry-segments-and-forecast-2023- 2019-02-11 $74B global Vision Care market $11B Global Contact Lens market USD $31B Consumer Smart Glasses market (Forecast 2023)
  • 9. 9 INNOVEGA REVENUE MODEL • License of intellectual property to eyewear and contact lens manufacturers, and to distributors that will sell and market the combined system • Multiple revenue streams: Upfront license fee; future royalties based on sales or profits; NRE (Non-recurring engineering) fees to fund Innovega collaboration • Innovega also develops and fabricates working contact lens and eyewear prototypes and limited production runs • Upfront licenses fees could be seven figures or more • Glasses royalties could be a percentage of price paid by the patient • Contact lens royalties could be a percentage of recurring revenue from disposable lenses • Non-recurring engineering (NRE) fees could be seven figures or more 9
  • 10. 10 GO-TO-MARKET STRATEGY CAPITAL-EFFICIENT STRATEGIC PARTNERSHIP MODEL 1. CORE: 15 M VISUALLY IMPAIRED PATIENTS • Glasses fitted with high magnification camera • Provide panoramic and magnified world-view • Meets patient lifestyle demand for “glasses” 2. UPSIDE MARKETS: MASS MARKET CONSUMERS • Consumers want mobility and glasses style • Consumers expect big, rich media • TENCENT is a lead investor / potential partner 10 Today’s Unacceptable Goggles
  • 11. 11 UPSIDE CONSUMER MARKETS THOSE CONSUMERS WHO WANT OR NEED STYLISH GLASSES VS. 11
  • 12. 12 WEARERS NEED THESE “10” FEATURES Comfort 1. Lightweight, balanced (2-3 oz) 2. No Eyestrain or headaches (“solve” vergence-accommodation conflicts!) 3. Integrated Vision Correction (62% of humans require vision correction) 4. Socially Comfortable: Any Style, Normal Glasses High Performance 5. High-resolution / Eye-limited, Retinal Display (1.2 arc-minute resolution) 6. Panoramic, Unobstructed Field of View (over 100 degrees) 7. Highest Image Quality, High-efficiency screens (ex. OLED) Many Configurations and Applications 8. VR/AR/MR (today’s and future configurations) 9. Any Image Source (Microdisplay screens, Pico-projectors) 10. Expandable and Extendable (ex. Integrated Eye-tracking, ex. 5g Edge device) 12
  • 13. 13 EMACULATM UNIQUELY DELIVERS ALL “10” FEATURES Comfort 1. Lightweight, balanced (2-3 oz) 2. No Eyestrain or headaches (“solve” vergence-accommodation conflicts!) 3. Integrated Vision Correction (62% of humans require vision correction) 4. Socially Comfortable: Any Style, Normal Glasses High Performance 5. High-resolution / Eye-limited, Retinal Display (1.2 arc-minute resolution) 6. Panoramic, Unobstructed Field of View (over 100 degrees) 7. Highest Image Quality, High-efficiency screens (ex. OLED) Many Configurations and Applications 8. VR/AR/MR (today’s and future configurations) 9. Any Image Source (Microdisplay screens, Pico-projectors) 10. Expandable and Extendable (ex. Integrated Eye-tracking, ex. 5g Edge device) 13
  • 14. 14 PARTNER BUSINESS MODEL - STATUS • Innovega delivers core technology, prototypes, applications • Partners “brand” glasses / lenses • Multiple revenue streams • Existing relationships or discussions with these global companies => 14
  • 15. 15 KEY INVESTORS, DIRECTORS, AND LEADERSHIP World’s largest video game company & world’s largest social media company Med-Tech Investment Firm VC focused on gaming and social media Jeff Xiong, FORMER CTO, TENCENT Shane Kim, INTERIM CEO, GAMESTOP; FORMER VP MSFT XBOX Jerome Legerton, OD, CO-FOUNDER SynergEyes Steve Willey, CO-FOUNDER MicroVision Steve Willey, MBA CEO Jerome Legerton, OD CHIEF CLINICAL OFFICER Jay Marsh, M Sc EE VP ENGINEERING Bill Meyers, PhD VP CONTACT LENSES Mark Freeman, PhD DIRECTOR OPTICS & PHOTONICS Peter Schuster, CPA DIRECTOR FINANCE INVESTORS DIRECTORS LEADERSHIP TEAM 15
  • 16. 16 BUSINESS, CLINICAL, SCIENTIFIC ADVISORY BOARDS Phil Molyneux, Consumer Electronics REGIONAL PRESIDENT DYSON. FORMER PRESIDENT, SONY ELECTRONICS, INC. N.A. Avram Miller, Capital Formation CO-FOUNDER INTEL CAPITAL. FORMER VP, BUSINESS DEVELOPMENT, INTEL CORP. Dan Spira, Healthcare FORMER NORTH AMERICA VP, BAUSCH & LOMB WITH RESPONSIBILITIES ACROSS EYE HEALTH, SKINCARE AND AESTHETICS; FORMER VP, JOHNSON & JOHNSON Jayson Chi, Video Game industry FORMER PARTNER MCKINSEY GROUP (GLOBAL LEAD, VIDEO GAMING PRACTICE) Robert Simmonds, Mobile Carrier FOUNDER, FORMER CHAIRMAN OF CLEARNET COMMUNICATIONS. ACQUIRED BY TELUS CORP FOR $6B Joe Barr, OD, MS FORMER GLOBAL VP FOR CLINICAL AND MEDICAL AFFAIRS, BAUSCH & LOMB; EMERITUS PROFESSOR THE OHIO STATE UNIVERSITY Mark Bullimore, MCOptom, PhD FORMER FDA OPHTHALMIC DEVICE PANEL MEMBER; FDA EXPERT ON VISION ASSESSMENT; DEAN MARSHALL B. KETCHUM UNIVERSITY, COLLEGE OF OPTOMETRY Richard Lindstrom, MD FOUNDER AND ATTENDING SURGEON MINNESOTA EYE CONSULTANTS; ADJUNCT PROFESSOR EMERITUS, UNIVERSITY OF MINNESOTA DEPARTMENT OF OPHTHALMOLOGY, OPHTHALMOLOGY EXPERT IN MEDICAL DEVICES AND CORNEAL AND CATARACT SURGERY Steve Schallhorn, MD OPHTHALMOLOGY EXPERT IN MEDICAL DEVICES AND CORNEAL AND CATARACT SURGERY; FORMER DIRECTOR, NAVAL REFRACTIVE SURGERY CENTER SAN DIEGO Jim Schwiegerling, PhD PROFESSOR, UNIVERSITY OF ARIZONA - OPHTHALMOLOGY AND VISION SCIENCE; OPTICS EXPERT 16
  • 17. 17 STATUS OF EMACULA U.S. FDA PROCESS • In-person Pre‐submisson FDA meeting has occurred • Phase II clinical trials underway; Pre-clinical testing underway • Phase III FDA clinical trial will start upon Phase II trial completion • Phase III (Part 1) • 510(k) process for approval of lens material • 510(k) process is a premarket submission made to FDA to demonstrate that a non-significant risk device (Class II) to be marketed is substantially equivalent in safety and effectiveness to an already FDA cleared Class II device for the same medical indications. • Phase III (Part 2) • FDA De Novo process for approval of the iOptik® display lens • No previously cleared device for viewing a near eye display 17
  • 18. PROGRESS AND PLANNEDMILESTONES This slide reflects management’s current views with respect to future events based on information currently available and is subject to risks and uncertainties. This slide is meant for illustrative purposes and does not represent guarantees of future results, levels of activity, performance, or achievements. 18
  • 19. 19 9,874,765 Dual path contact lens 2014/0138544 MEMS based Eye Tracking, 2 2017/0337706 Low Latency Gaze Tracker Patterned Polarizer 8,142,016 Lens-let Molding into Contact Lens Contact Lens Component Containing Molding 2016/0216534 Contact Lens with Non- Permeable Inserts 8,922,898 Wire Grid Polarizer in Lens 8,482,858 Deflection Optics 9,869,884 Contact Lens 2015/0084999 See Through Display with Pixilation Occlusion, 2 9,251,745 See Through Display with Pixilation Occlusion, 1 8,441,731 Direct View Transparent Display 2018/0090052 Large Field of View Head-worn Display 2016/0131910 TFD based display8,922,897 Pixilated Occlusion for TFD 8,520,309 Display and Non Display Path Foundational Case 8,786,520 Direct View Display in Eyewear 9,040,923 MEMS based Eye Tracking, 1 High Resolution Transparent Display Implanted Optical Device Camera Eyewear Methods of Fitting Display Eyewear SUCCESSFUL PATENT MANAGEMENT Display Systems Eye Tracking Filters Filed - Unpublished by USPTO Application in process Core (14) 1st Order (7) 2nd Order (5) 8,888,279 Filters with Lenslet 9,348,151 Molded lens with nanofilaments, 1 2015/0205146 Molded lens with nanofilaments, 2
  • 20. 20 SUMMARY • Experienced team has delivered $6M working systems • Valuable portfolio of domestic and foreign patents • Core Market of 15 million Visually Impaired Patients • Uniquely meets needs of Upside Consumer Markets • FDA Phase II trials near completion; Final Phase planned • Strategic partners invested $5.5M - led by Tencent • Discussions with Operating Partners and Investors • We welcome your involvement 20
  • Related Search
    Similar documents
    View more...
    We Need Your Support
    Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

    Thanks to everyone for your continued support.

    No, Thanks